LeMaitre Q3 2026 Financial Results
Q3 sales $68.0M (+11%), EPS $0.65 (-14%, +5% adj.); FY26 guide raised to $274.8M-$276.8M sales, $2.77-$2.82 EPS.
What this release says
LeMaitre reported Q3 2026 sales of $68.0mm, up 11%, with EPS of $0.65, down 14% as reported but up 5% excluding a prior-year tax credit benefit. It also declared a $0.25 quarterly dividend, bought certain vascular assets from B. Braun for $19.2mm, and raised its full-year outlook for sales and EPS. For a shareholder, the results show solid sales growth and a sizable cash balance, while the acquisition and higher operating costs are the items to watch.
Key figures
- Q3 2026 sales
- $68.0mm
- Q3 2026 EPS
- $0.65
- Cash at 9/30/2026
- $390mm
- B. Braun acquisition price
- $19.2mm
- Full-year 2026 sales guidance midpoint
- $275.8mm
- Quarterly dividend
- $0.25/share
Positive for shareholders
- Sales grew 11% (12% organic), led by grafts and shunts.
- Gross margin rose 90 bps excluding the prior-year tax credit, helped by higher prices and efficiencies.
- Cash increased by $13.5mm sequentially to $390mm.
- The company declared a $0.25 quarterly dividend, payable December 3, 2026.
Negative for shareholders
- Reported EPS fell 14% against a prior-year quarter that included a one-time tax credit.
- Operating expenses rose 21% as reported, which pressured operating income.
- The B. Braun acquisition uses $19.2mm of cash and its sales will take 18-24 months to transition.
- Headcount and sales rep count increased, adding to cost.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Organic growth:
- Sales growth excluding the effect of acquisitions and currency changes.
- ASP:
- Average selling price, the average price the company receives per unit sold.
- Employee Retention Tax Credit:
- A U.S. government tax credit for businesses that kept employees on payroll during the pandemic, received here as a one-time benefit in 2025.
- Non-GAAP:
- Financial measures that adjust standard accounting results to exclude certain items, so they are not directly comparable to GAAP figures.
FAQ
How much did LeMaitre's sales grow in Q3 2026?
Sales were $68.0mm, up 11% from Q3 2025, or 12% on an organic basis. The release said 7% came from price and 5% from units.
What is LeMaitre's full-year 2026 guidance?
The company expects full-year 2026 sales of $274.8mm to $276.8mm and EPS of $2.77 to $2.82, with the midpoint representing 11% sales growth and 18% adjusted EPS growth.
What is the B. Braun acquisition expected to contribute?
LeMaitre expects about $150,000 of B. Braun product sales and break-even operating income in Q4 2026, with sales transitioning into its channel over the next 18-24 months.
Historical context for LMAT
Across the 15 sessions after earlier LMAT headlines, the stock closed higher 7 times and lower 8 times, with a median move of 1.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LMAT | SPY |
|---|---|---|---|
| Oct 13, 2026 | LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026 | -1.6% | -0.0% |
| Aug 28, 2026 | LeMaitre to Participate at Upcoming Investor Conferences in September | +1.0% | -0.2% |
| Aug 7, 2026 | LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference | +0.8% | +0.6% |
| Aug 5, 2026 | Lemaitre Vascular downgraded by Barrington Researchand 1 other headline that session | -25.3% | -0.2% |
| Jul 15, 2026 | LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026 | +2.0% | +0.4% |
| May 21, 2026 | LeMaitre to Participate at Upcoming Investor Conferences in June | -1.9% | +0.2% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2006
Follow LMAT and get a push notification the moment its next story breaks.